| 发明名称 |
RNA Formulation for Immunotherapy |
| 摘要 |
The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA. |
| 申请公布号 |
US2015086612(A1) |
申请公布日期 |
2015.03.26 |
| 申请号 |
US201314388192 |
申请日期 |
2013.03.25 |
| 申请人 |
BioNTech AG ;TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz Gemeinnützge GmbH ;Universitätsmedizin der Johannes Gutenber-Universität Mains |
发明人 |
Sahin Ugur;Haas Heinrich;Kreiter Sebastian;Diken Mustafa;Fritz Daniel;Meng Martin;Kranz Lena Mareen;Reuter Kerstin |
| 分类号 |
A61K48/00;A61K39/00;A61K9/127 |
主分类号 |
A61K48/00 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A pharmaceutical composition comprising nanoparticles which comprise RNA encoding at least one antigen, wherein:
(i) the number of positive charges in the nanoparticles does not exceed the number of negative charges in the nanoparticles and/or (ii) the nanoparticles have a neutral or net negative charge and/or (iii) the charge ratio of positive charges to negative charges in the nanoparticles is 1.4:1 or less and/or (iv) the zeta potential of the nanoparticles is 0 or less. |
| 地址 |
Mainz DE |
